{
    "nctId": "NCT00896467",
    "briefTitle": "Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy",
    "officialTitle": "Psychological and Emotional Impacts of Participation in Randomized Clinical Studies in Medical Oncology",
    "overallStatus": "TERMINATED",
    "conditions": "Anal Cancer, Anxiety Disorder, Breast Cancer, Depression, Esophageal Cancer, Gallbladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer, Small Intestine Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Quality of life as assessed by the QLQ-30 questionnaire",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed cancer\n\n  * Metastatic disease for which the median progression-free survival is \u2265 4 months\n  * Breast, digestive, kidney, lung\n* Receiving first-line antitumor therapy (i.e., chemotherapy or targeted therapy) as part of either:\n\n  * Phase II or III randomized clinical trial\n  * Standard treatment off-trial\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status (PS) 0-3 or Karnofsky PS 50-100%\n* No psychological or physical inability to respond to a questionnaire\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* No psychotropic treatment, except for antidepressants, anxiolytics, or sleeping pills taken for more than 30 days",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}